<DOC>
	<DOC>NCT01404390</DOC>
	<brief_summary>This study will be conducted as an open label, single centre, Phase I study of PI3K (phosphatidyl inositol 3 kinase) inhibitor BAY80-6946 in Japanese patients with advanced or refractory solid tumours. The eligible subjects will be dosed intravenously at Day 1, Day 8 and Day 15 with three weeks on and one week off in each treatment cycle.</brief_summary>
	<brief_title>Japanese BAY80-6946 Monotherapy Phase I Study</brief_title>
	<detailed_description />
	<criteria>Cancer patients Japanese patients, who are at least 20 years of age Histological or cytological documentation of nonhematologic, malignant solid tumours, excluding primary brain or spinal tumours, with no past or current involvement in the central nervous system (CNS) At least one measurable lesion or evaluable disease according to RECIST (version 1.1) Eastern Cooperative Oncology performance status (ECOGPS) of 0 or 1 Life expectancy of at least 12 weeks Advanced or refractory solid tumours not amenable to standard therapy, at the first screening examination/visit Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of first study treatment. Patients must have recovered from the toxic effects of the previous anticancer chemotherapy or immunotherapy by the investigator (with the exception of alopecia). Radiotherapy to target lesions during study or within 4 weeks of first study treatment Investigational drug therapy outside of this trial during or within 4 weeks of first study treatment Current diagnosis of Type I or II diabetes mellitus or fasting blood glucose level &gt;125 mg/dL at screening, and/or HbA1c&gt;/= 6.5% Past and current histories of cardiac disease congestive heart failure &gt; New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset of angina within 3 months prior to study entry or unstable angina or ventricular cardiac arrhythmias requiring antiarrhythmic therapy Active and clinically serious infections &gt;Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCICTCAE] version 4.03) Uncontrolled hypertension defined as systolic blood pressure &gt;150 mm Hg or diastolic pressure &gt; 90 mm Hg, despite optimal medical management Patients undergoing renal dialysis Pregnant or breast feeding women</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Japanese</keyword>
</DOC>